Equities

Essex Bio-Technology Ltd

Essex Bio-Technology Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.26
  • Today's Change-0.01 / -0.44%
  • Shares traded150.00k
  • 1 Year change-19.57%
  • Beta0.5326
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of HKD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments515543671
Total Receivables, Net637500714
Total Inventory638498
Prepaid expenses------
Other current assets, total308764
Total current assets1,2451,2141,547
Property, plant & equipment, net406401352
Goodwill, net565751
Intangibles, net1,055979775
Long term investments402857
Note receivable - long term0110
Other long term assets117.6864
Total assets2,8282,7122,863
LIABILITIES
Accounts payable11114.47
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases238108156
Other current liabilities, total563443529
Total current liabilities811561690
Total long term debt56382409
Total debt294490565
Deferred income tax373830
Minority interest------
Other liabilities, total------
Total liabilities9049811,129
SHAREHOLDERS EQUITY
Common stock575758
Additional paid-in capital737373
Retained earnings (accumulated deficit)1,9361,7131,556
Treasury stock - common------
Unrealized gain (loss)181818
Other equity, total(160)(130)29
Total equity1,9241,7311,734
Total liabilities & shareholders' equity2,8282,7122,863
Total common shares outstanding568572576
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.